Background: Systemic corticosteroids are one of the most commonly used therapeutic modalities for patients with extensive alopecia areata (AA), although they entail several drawbacks. Objective: To determine the best modality for systemic corticosteroid use in terms of their efficacy, relapse rate, and side effects. Methods: Fifty-one patients with single or multiple AA (AA/multiplex) and 38 patients with alopecia totalis or AA universalis (AA totalis/universalis) were enrolled in this open study. They were randomly divided into three groups depending on the time of their initial visit. They were administered (1) oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group), (2) intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group), and (3) pulse therapy (PT) using oral predonine 80 mg for 3 consecutive days once every 3 months (PT group). After the treatment, each treatment modality was evaluated by the response rate, relapse rate, and side effect profile. Results: The response rate of AA/multiplex was significantly better in the imTA group than in the Dex group. The overall relapse rate and that of AA totalis/universalis were significantly better in the PT group than in the Dex group. Dysmenorrhea was the most common and problematic side effect. Impairment of the adrenocortical reserve was seen in 7% of the PT group and 23% of the imTA group, which was recov ered without any further medical treatment. Conclusion: imTA or pulse therapy is effective for AA and has an acceptable level of side effects. The development of a new strategy to reduce the relapse rate is needed.

1.
Madani S, Shapiro J: Alopecia areata update. J Am Acad Dermatol 2000;42:549–566.
2.
Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R, McElwee KJ: Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 2001;7:213–230.
3.
MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG: Guidelines for the management of alopecia areata. Br J Dermatol 2003;149:692–699.
4.
Köse O, Safali M, Tasten HB, Gur AR: Mycophenolate mofetil in extensive alopecia areata: no effect in seven patients. Dermatology 2004;209:69–70.
5.
Abell E, Munro DD: Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973;88:55–59.
6.
Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O: Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979;115:1254–1255.
7.
Nelson DA, Spielvogel RL: Anthralin therapy for alopecia areata. Int J Dermatol 1985;24:606–607.
8.
Fiedler-Weiss VC: Topical minoxidil solution (1 and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987;16:745–748.
9.
Fiedler-Weiss VC, Buys CM: Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123:1491–1493.
10.
Caserio RJ: Treatment of alopecia areata with squaric acid dibutylester. Arch Dermatol 1987;123:1036–1041.
11.
Naldi L, Parazzini F, Cainelli T: Role of topical immunotherapy in the treatment of alopecia areata. Quality analysis of articles published between January 1977 and January 1988 about three treatments. Reading Group. J Am Acad Dermatol 1990;22:654–656.
12.
van der Steen PH, van Baar HM, Perret CM, Happle R: Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991;24:253–257.
13.
Hoting E, Boehm A: Therapy of alopecia areata with diphencyprone. Br J Dermatol 1992;127:625–629.
14.
Gordon PM, Aldrige RD, McVittie E, Hunter JA: Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow-up. Br J Dermatol 1996;134:869–871.
15.
Claudy AL, Gagnaire D: PUVA treatment of alopecia areata. Arch Dermatol 1983;119:975–978.
16.
Lassus A, Eskelinen A, Johansson E: Treatment of alopecia areata with three different PUVA modalities. Photodermatology 1984;1:141–144.
17.
Mitchell AJ, Douglass MC: Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985;12:644–649.
18.
Taylor CR, Hawk JL: PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 1995;133:914–918.
19.
Healy E, Rogers S: PUVA treatment for alopecia areata – does it work? A retrospective review of 102 cases. Br J Dermatol 1993;129:42–44.
20.
Kopera D, Wolf P: Failure of prolonged extracorporeal photopheresis in the treatment of alopecia areata universals in two patients. Dermatology 2003;207:427–428.
21.
Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS, Hamilton TA, Tellner DC, Griffiths CE, Voorhees JJ: Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 1990;22:242–250.
22.
Ferrando J, Grimalt R: Partial response of severe alopecia areata to cyclosporine A. Dermatology 1999;199:67–69.
23.
Perriard-Wolfensberger J, Pasche-Koo F, Mainetti C, Labarthe MP, Salomon D, Saurat JH: Pulse of methylprednisolone in alopecia areata. Dermatology 1993;187:282–285.
24.
Sharma VK: Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996;35:133–136.
25.
Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH: Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998;39:597–602.
26.
Michalowski R, Kuczynska L: Long-term intramuscular triamcinolon-acetonide therapy in alopecia areata totalis and universalis. Arch Dermatol Res 1978;261:73–76.
27.
Burton JL, Shuster S: Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975;55:493–496.
28.
Burton J, Shuster S: Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975;55:493–496.
29.
Sharma VK: Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996;35:133–136.
30.
Seiter S, Ugurel S, Tilgen W, Reinhold U: High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 2001;202:230–234.
31.
Olsen EA, Carson SC, Turney EA: Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;128:1467–1473.
32.
McElwee KJ, Yu M, Park SW, Ross EK, Finner A, Shapiro J: What can we learn from animal models of alopecia areata? Dermatology 2005;211:47–53.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.